openPR Logo
Press release

RAS-acting Agents Market Revenue to Cross $13.4 Billion by 2031 to Rise at a Stellar CAGR of 4.2% | Exclusive Research by Transparency Market Research

03-13-2024 11:56 AM CET | Health & Medicine

Press release from: Transparency Market Research

RAS-acting Agents Market Revenue to Cross $13.4 Billion by 2031

The RAS-Acting Agents Market focuses on pharmaceutical products that target the renin-angiotensin system (RAS), a key regulator of blood pressure, fluid, and electrolyte balance. RAS-acting agents modulate the activity of angiotensin-converting enzyme (ACE), angiotensin II receptors (ARBs), and aldosterone receptors, offering therapeutic benefits in cardiovascular and renal diseases characterized by RAS dysregulation. This research report aims to provide a comprehensive analysis of the market dynamics, therapeutic indications, key players, recent developments, and future prospects within the RAS-acting agents sector.

RAS-acting Agents market is estimated to attain a valuation of US$ 13.4 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.2% during the forecast period, 2023-2031

Get a Sample Copy of the RAS-acting Agents Market Research Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85539&utm_source=openpr_amitugare&utm_medium=openpr

The significant players operating in the global RAS-acting Agents market are

Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, and Johnson & Johnson

Market Dynamics

Clinical Indications: RAS-acting agents are indicated for the management of hypertension, heart failure, diabetic nephropathy, and chronic kidney disease, where RAS dysregulation contributes to volume overload, systemic vasoconstriction, and end-organ damage, necessitating targeted pharmacological interventions to mitigate cardiovascular and renal risk factors.

Guideline-Directed Therapy: RAS-acting agents are integral components of evidence-based guidelines for cardiovascular risk reduction and management of hypertension and heart failure, emphasizing their role in optimizing blood pressure control, preserving renal function, and reducing cardiovascular morbidity and mortality in high-risk patient populations.

Combination Therapy: RAS-acting agents are often used in combination with other antihypertensive medications, including diuretics, beta blockers, calcium channel blockers, and direct renin inhibitors, as well as lipid-lowering drugs and glucose-lowering agents, to achieve comprehensive cardiovascular risk reduction and optimize therapeutic outcomes in patients with complex comorbidities.

Therapeutic Indications

The RAS-Acting Agents Market encompasses a range of therapeutic indications, including:

Hypertension: RAS-acting agents are first-line agents for the management of hypertension, reducing blood pressure through vasodilation, natriuresis, and inhibition of aldosterone secretion, thereby lowering cardiovascular risk and preventing end-organ damage in hypertensive patients.

Heart Failure: RAS-acting agents are integral components of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF), reducing morbidity and mortality by blocking maladaptive neurohormonal activation, reversing cardiac remodeling, and improving left ventricular function and myocardial contractility.

Diabetic Nephropathy: RAS-acting agents are renoprotective in diabetic nephropathy, slowing the progression of renal disease, reducing proteinuria, and preserving glomerular filtration rate (GFR) by inhibiting intrarenal RAS activation, reducing glomerular pressure, and preventing glomerular sclerosis and interstitial fibrosis.

Recent Developments

Precision Medicine Approaches: Biomarker-guided therapy, genetic testing, and personalized treatment algorithms identify high-risk patients who may benefit from RAS-acting agents, allowing for individualized dosing, titration, and selection based on patient-specific factors, renal function, electrolyte status, and cardiovascular risk profile.

Novel Formulations: Extended-release formulations, fixed-dose combinations, and novel drug delivery systems enhance the pharmacokinetic profile, bioavailability, and therapeutic efficacy of RAS-acting agents, offering convenient dosing regimens and sustained clinical benefits in patients with cardiovascular and renal diseases.

Buy this Premium Research Report: - https://www.transparencymarketresearch.com/checkout.php?rep_id=85539<ype=S

Market Segmentation -

Drug Class
ACE Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Renin Inhibitors
Aldosterone Antagonists
Others (diuretics)

Indication
Hypertension
Heart Failure
Chronic Kidney Disease
Diabetic Nephropathy
Coronary Artery Disease

Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

This Report lets you identify the opportunities in RAS-acting Agents Market by means of a region:

North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

Key Features of the RAS-acting Agents Market Report: -

➤ Analyze competitive developments such as expansions, deployments, new product launches, and market acquisitions.

➤ Examine the market opportunities for stakeholders by identifying higher growth sections.

➤ To study and analyze the global RAS-acting Agents industry status and forecast including key regions.

➤ An in-depth analysis of key product segments and application spectrum, providing strategic recommendations to incumbents and new entrants to give them a competitive advantage over others.

➤ It provides a comprehensive analysis of key regions of the industry as well as a SWOT analysis and Porter's Five Forces analysis to provide a deeper understanding of the market.

➤ It helps you make strategic business decisions and investment plans.

More Trending Reports by Transparency Market Research -

Gastrointestinal Bleeding Treatment Market: https://www.globenewswire.com/en/news-release/2024/03/04/2839301/32656/en/Gastrointestinal-Bleeding-Treatment-Market-Set-to-Reach-USD-824-9-million-by-2031-with-a-5-4-CAGR-Growth-Transparency-Market-Research-Inc.html

Hypopigmentation Disorder Treatment Market: https://www.globenewswire.com/en/news-release/2024/03/04/2839337/32656/en/Hypopigmentation-Disorder-Treatment-Market-to-Reach-USD-11-2-billion-by-2031-Expanding-at-a-CAGR-of-6-0-Transparency-Market-Research-Inc.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RAS-acting Agents Market Revenue to Cross $13.4 Billion by 2031 to Rise at a Stellar CAGR of 4.2% | Exclusive Research by Transparency Market Research here

News-ID: 3427388 • Views:

More Releases from Transparency Market Research

Global Solar Powered Agricultural Dryer Market to Exceed USD 2.4 Billion by 2031 - Transparency Market Research
Global Solar Powered Agricultural Dryer Market to Exceed USD 2.4 Billion by 2031 …
The global solar powered agricultural dryer market, valued at US$ 1.6 billion in 2022, is projected to grow at a CAGR of 5.8% from 2023 to 2031, reaching US$ 2.4 billion by the end of 2031. Rising investments in renewable energy, growing awareness of sustainable agricultural practices, and the rapid expansion of the agricultural sector driven by population growth are key factors fueling market growth. Uncover essential discoveries and trends from
Technetium-99m Market Forecast 2034: Rising Demand for Diagnostic Imaging and Radiopharmaceuticals to Propel Market Expansion | Transparency Market Research, Inc
Technetium-99m Market Forecast 2034: Rising Demand for Diagnostic Imaging and Ra …
The global Technetium‐99m Market was valued at US$ 6.0 Billion in 2023 and is projected to grow at a CAGR of 3.3% from 2024 to 2034, surpassing US$ 8.6 Billion by the end of the forecast period. Advancements in nuclear imaging infrastructure, government-backed healthcare initiatives, and an increasing demand for precise diagnostic procedures are fueling this growth. Discover essential conclusions and data from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=77100 Analysts' Viewpoint The Technetium‐99m
Equine Diagnostic Services Market Outlook 2030: From US$ 168 Million in 2019 to US$ 280 Million by 2030, Driven by Rising Equine Diseases and Diagnostic Advancements
Equine Diagnostic Services Market Outlook 2030: From US$ 168 Million in 2019 to …
The global Equine Diagnostic Services Market, valued at approximately US$ 168 million in 2019, is projected to expand at a compound annual growth rate (CAGR) of ~5% from 2020 to 2030, reaching around US$ 280 million by 2030. Equine diagnostic services, encompassing tests like genetic, infectious disease, and imaging diagnostics, are critical for managing horse health in veterinary hospitals, clinics, and mobile settings. The market is driven by increasing equine
Digital Printing Market to Reach USD 54.4 Billion by 2034, Growing at a CAGR of 6.1%
Digital Printing Market to Reach USD 54.4 Billion by 2034, Growing at a CAGR of …
The digital printing market is experiencing strong growth, driven by rapid technological advancements, rising demand for personalized and on-demand printing, and an increasing focus on sustainable solutions. Digital printing allows for the direct transfer of digital files onto a wide range of substrates, offering high-resolution output with greater speed and flexibility. Its adaptability has led to broad adoption across industries such as packaging, textiles, publishing, and advertising-sectors where customization, efficiency,

All 5 Releases


More Releases for RAS

Ras Al Khaimah's Trusted Physiotherapy Service
Unlock Your Body's Potential with Physio Home Professional Physiotherapy Services At Physio Home in Ras Al Khaimah, we understand the pivotal role that physiotherapy plays in enhancing one's quality of life. Our dedicated team of experts is committed to providing personalized care and effective solutions tailored to your unique needs. With a focus on empowering mobility and promoting holistic well-being, we bring top-tier physiotherapy services directly to your doorstep. Whether you're
Ras Aquaculture Market Leading Players, Competitive Landscape, Strategy, Forecas …
Ras Aquaculture Market Overview: Recirculating Aquaculture Systems (RAS) represent an innovative and sustainable approach to aquaculture, focusing on the intensive farming of aquatic organisms in a controlled environment. Unlike traditional aquaculture methods that rely heavily on large water bodies, RAS involves the continuous recirculation and treatment of water within a closed-loop system. This method significantly reduces water usage, minimizes environmental impact, and allows for year-round production regardless of external weather conditions.
RAS Inhibitors Market Size, Share, Growth Analysis 2023
The global ras inhibitors market size was valued at USD x billion in 2022 and is poised to grow at a significant CAGR of x% during the forecast period 2023-29. Ongoing research and development efforts in the RAS-inhibitors agents market are expanding its scope. New drugs targeting various renin-angiotensin system components, such as renin, ACE, and angiotensin II receptors, are being explored. The market is also witnessing increased interest
RAS Targeting Therapies Market, 2021-2031 by Roots
Roots Analysis has announced the addition of “RAS Targeting Therapies Market, 2021-2031” report to its list of offerings. To order this 140+ page report, which features 95+ figures, please visit https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html Key Inclusions  A detailed overview of the current market landscape of RAS targeting therapies, along with information on several relevant parameters, such as current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II, phase I /
RAS Luxury Oils Launches Eco drive Campaign
Luxury Natural Skincare and wellness brand promotes Sustainability for the Environment One Bottle at a Time #RecyclewithRAS New Delhi, 26th November 2018: “Farm to bottle’ luxury natural skincare and wellness brand RAS Luxury Oils has launched its eco drive campaign, #RecyclewithRAS to encourage customers, to promote the concept of three R’s -“Reduce, Reuse and Recycle”, and to regain the sustainability of the packaging among customers. On returning 1 empty primary bottle
The Kurchatov Institute Has Chosen 2X RAS
Kurchatov Institute - supported by Aflex Distribution - Has Chosen 2X Remote Application Server "We are very positive about the adoption of a 2X solution. At the moment we are using 2X RAS for its main features: application delivery and load balancing. We are very satisfied with the seamless end-user experience and the high availability gained with the workload-based server load balancing. In future, we plan to use 2X RAS